Our Expertise: Diagnosis Intelligence & Early Interception

A collaborative diagnostics framework for accelerating the discovery and product lifecycle of rare, complex, and high-velocity diseases.

Bridging Clinical Care with Global Breakthroughs

The gap between clinical care and clinical research is costing lives. Statistics show that up to 80% of rare, complex, and high-velocity disease patients are treated in community settings that remain disconnected from the global research ecosystem.

Regal Intel bridges this gap. We are a 501(c)(3) non-profit research consortium that deploys a collaborative diagnostics framework to solve the complexity of diagnosing and intercepting high-velocity conditions. We don't just advise; we establish the infrastructure that allows actionable diagnosis intelligence to flow securely between those who treat patients and those who develop cures, without compromising patient sovereignty.

Connect with us

For Hospitals & Health Systems

Your Clinical Insights Flow. Patient Privacy Stays.

Historically, participating in clinical research required extracting sensitive patient files to centralized databases—a privacy and GDPR compliance risk many institutions cannot take. We have transformed this model through our Sovereign "Code-to-Data" architecture.

Sovereign Intelligence: Our diagnostics framework operates seamlessly within your institution’s trusted environment. Our algorithms interpret clinical patterns locally by calculating the biological velocity of a patient's symptoms, providing your team with actionable diagnosis intelligence to catch "Metabolic Masqueraders" before a catastrophic crisis occurs, while ensuring zero patient records ever leave your facility.
Democratized Access: By joining the Regal Intel consortium, community hospitals can offer their patients access to global research insights, diagnosis intelligence, and early interception tools previously reserved for major academic centers.
Mission & Reputation: Turn your clinical expertise into a vital contributor to global research without compromising institutional control or jurisdictional compliance.

Connect with us

For Biotech, Pharma & Life Sciences

De-Risking the Path to Approval

Developing therapies for "Small N" patient populations presents unique challenges: identifying patients is difficult, and proving efficacy without large placebo groups is often unethical or impossible. We provide the high-fidelity evidence required to satisfy global regulators and rescue stranded therapeutics for rare, complex, and high-velocity diseases.

Regulatory-Grade Synthetic Control Arms (SCA): We utilize advanced biological modeling constrained by physiological kinetics to generate high-fidelity external control arms that are statistically exchangeable with real-world subjects, reducing the ethical and logistical burden of recruiting placebo groups for high-acuity conditions.
High-Fidelity Real-World Evidence (RWE): We move beyond simple billing codes. Our diagnostics framework interprets unstructured clinical notes to extract the deep phenotypic data and "Phenotypic Velocity" required for robust regulatory submissions and identifying off-label indication expansions.
Global Market Access: We align evidence-generation strategies with both FDA and EMA requirements, initiating and leveraging engagements with the FDA CPIM pathway and IRDiRC Task Force, ensuring the resulting interpretation supports global approval and Bioresearch Monitoring (BIMO) inspection readiness.

Connect with Us

Our Specialized Expertise

We combine our collaborative diagnostics framework with decades of regulatory experience. Our team acts as a fiduciary strategic extension of yours, navigating the complex milestones of orphan drug development and natural history modeling.

Regulatory Strategy & Intelligence

We specialize in the specific pathways designed to accelerate rare, complex, and high-velocity disease therapies.

Designations: Strategic support for Orphan Drug, Rare Pediatric Disease (PRV), and Breakthrough Therapy designations.
Regulatory Liaison: Preparation for FDA Complex Innovative Design (CID) interactions, INTERACT meetings, IND, and BLA meetings.
Global Submissions: Managing the lifecycle of IND, NDA, and BLA (US) alongside MAA (Europe) filings.

Physiologically-Grounded Interpretation

Manufacturing and validating complex biologics for small populations requires precision.

Biological Integrity: Our systems ensure that all synthetic evidence remains anchored in known human pathophysiology and metabolic laws (Stoichiometric Governance), eliminating the risk of algorithmic "hallucinations".
Pharmacogenomic Insights: We utilize differentiable reparameterization to isolate drug-induced responses from natural disease progression, identifying true therapeutic efficacy even in highly diverse metabolic phenotypes.

Evidence Generation & Data Integrity

Transforming raw clinical encounters into regulatory-grade assets without moving the data.

ALCOA+ Compliance: Every interpretation is timestamped and signed with an immutable SHA-256 cryptographic hash, proving data originality and provenance to satisfy strict FDA BIMO requirements.